Data readout from Phase 3 clinical trial in the People s Republic of China evaluating F351 for the treatment of CHB-associated liver fibrosis expected by early 2025 U.S. Phase 2a clinical trial.
Gyre Therapeutics, Inc : Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.